Correction: On the mechanism of anti-CD39 immune checkpoint therapy

• Sara Bedrose,
• Kevin Charles Miller,
• Lina Altameemi,
• Mohamed S Ali,
• Sameh Nassar,
• Naveen Garg,
• Marilyne Daher,
• Keith D Eaton,
• Jeffrey Thomas Yorio,
• Davey B Daniel,
• Keith C Bible,
• Ashish V Chintakuntlawar,
• Mouhammed Amir Habra

Affiliations

Sara Bedrose

Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Kevin Charles Miller

School of Medicine, Mayo Clinic, Rochester, Minnesota, USA

Lina Altameemi

Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Mohamed S Ali

Section of Endocrinology, Diabetes and Metabolism, University of Texas Health Science Center at Houston, Houston, Texas, USA

Sameh Nassar

Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Naveen Garg

Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Marilyne Daher

Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Keith D Eaton

Department of Medical Oncology, University of Washington, Seattle, Washington, USA

Jeffrey Thomas Yorio

Texas Oncology Austin Central, Austin, Texas, USA

Davey B Daniel

Tennessee Oncology, Chattanooga, Tennessee, USA

Keith C Bible

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA

Ashish V Chintakuntlawar

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA

Mouhammed Amir Habra

Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, University of Texas MD Anderson Cancer Center, Houston, Texas, USA